83%Confidence
0Views
FDASource
2026-04-02Date
Summary
Rising Pharma's Temozolomide stability failure suggests potential quality issues in oncology generic manufacturing, which could affect patient safety in critical cancer treatments. This may impact their ability to compete in the competitive generic oncology market and trigger additional regulatory scrutiny.
Actionable: Review positions in Rising Pharma and monitor for potential impacts on other products manufactured at the same Taiwan facility.
AI Confidence: 83%
Data Points
firmRising Pharma Holding, Inc.
classificationClass II
statusOngoing
distributionNationwide within the U.S
productProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now